The U.S. hemostatic sealants in arterial surgery market size was estimated at USD 95.5 million in 2025 and is projected to reach USD 114.6 million by 2033, growing at a CAGR of 2.3% from 2026 to 2033. Market growth is primarily driven by the increasing burden of peripheral artery disease (PAD), aortic aneurysms, and other vascular disorders requiring surgical intervention.
According to the CDC, nearly 8.5 million Americans are affected by PAD, with the disease being particularly prevalent among the aging population and patients with diabetes, hypertension, obesity, and smoking-related cardiovascular conditions. The growing volume of arterial bypass procedures, aneurysm repairs, carotid endarterectomies, and other complex vascular surgeries is increasing the demand for advanced hemostatic sealants that can reduce intraoperative bleeding, improve surgical efficiency, and lower the risk of postoperative complications.
In addition, the rising adoption of minimally invasive and endovascular procedures, along with continuous technological advancements in bioresorbable and synthetic sealant products, is further supporting market expansion. Government initiatives and healthcare organizations are also emphasizing improved cardiovascular care and surgical outcomes, encouraging hospitals and surgical centers to adopt advanced bleeding management solutions. Together, these factors are contributing to the increasing utilization of hemostatic sealants in arterial surgery across the U.S.
The U.S. is the most dominant and most procedure-intensive national market for hemostatic sealants in arterial surgery in North America. Its combination of the world’s largest absolute vascular surgery caseload, a rapidly aging cardiovascular patient population, a well-resourced hospital infrastructure, and a favorable FDA regulatory environment makes it the single most important geography for hemostatic sealant manufacturers operating in the arterial surgery segment. The four key disease indications, namely, aortic aneurysms, peripheral artery disease, carotid artery disease, and other acute conditions, including aortic dissection and traumatic arterial injury, each generate a distinct and well-defined CPT-coded procedural demand base that directly drives hemostatic sealant utilization.
This product will be delivered within 1-3 business days.
According to the CDC, nearly 8.5 million Americans are affected by PAD, with the disease being particularly prevalent among the aging population and patients with diabetes, hypertension, obesity, and smoking-related cardiovascular conditions. The growing volume of arterial bypass procedures, aneurysm repairs, carotid endarterectomies, and other complex vascular surgeries is increasing the demand for advanced hemostatic sealants that can reduce intraoperative bleeding, improve surgical efficiency, and lower the risk of postoperative complications.
In addition, the rising adoption of minimally invasive and endovascular procedures, along with continuous technological advancements in bioresorbable and synthetic sealant products, is further supporting market expansion. Government initiatives and healthcare organizations are also emphasizing improved cardiovascular care and surgical outcomes, encouraging hospitals and surgical centers to adopt advanced bleeding management solutions. Together, these factors are contributing to the increasing utilization of hemostatic sealants in arterial surgery across the U.S.
The U.S. is the most dominant and most procedure-intensive national market for hemostatic sealants in arterial surgery in North America. Its combination of the world’s largest absolute vascular surgery caseload, a rapidly aging cardiovascular patient population, a well-resourced hospital infrastructure, and a favorable FDA regulatory environment makes it the single most important geography for hemostatic sealant manufacturers operating in the arterial surgery segment. The four key disease indications, namely, aortic aneurysms, peripheral artery disease, carotid artery disease, and other acute conditions, including aortic dissection and traumatic arterial injury, each generate a distinct and well-defined CPT-coded procedural demand base that directly drives hemostatic sealant utilization.
U.S. Hemostatic Sealants in Arterial Surgery Market Report Segmentation
This report forecasts revenue growth at the country level and analyzes the latest industry trends in each sub-segments from 2021 to 2033. For this study, the analyst has segmented the U.S. hemostatic sealants in arterial surgery market report based on product, application, disease indication, and end use:Product Outlook (Revenue, USD Million, 2021-2033)
- Fibrin-based Sealants
- Synthetic/Polymer-based Sealants
- Combination Hemostats & Sealants
Application Outlook (Revenue, USD Million, 2021-2033)
- Arterial Surgery with Graft Replacement (Artificial Vessel Replacement)
- 35556, 35566
- 35656, 35661, 35666
- 35081, 35082, 35091, 35092, 35102, 35103
- 33858, 33859, 33863, 33864, 33871, 33875, 33877
- Arterial Repair/Reconstruction without Graft
- 35301
- 35371
- 35206
- 35286
- 35226, 35256
Disease Indication Outlook (Revenue, USD Million, 2021-2033)
- Aortic Aneurysms
- Peripheral Artery Disease
- Carotid Artery Disease
- Others
End Use Outlook (Revenue, USD Million, 2021-2033)
- Public Hospitals
- Private Hospitals
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. U.S. Hemostatic Sealants in Arterial Surgery Market Variables, Trends & Scope
Chapter 4. U.S. Hemostatic Sealants in Arterial Surgery Market: Product Estimates & Trend Analysis
Chapter 5. U.S. Hemostatic Sealants in Arterial Surgery Market: Application Estimates & Trend Analysis
Chapter 6. U.S. Hemostatic Sealants in Arterial Surgery Market: Disease Indication Estimates & Trend Analysis
Chapter 7. U.S. Hemostatic Sealants in Arterial Surgery Market: End Use Estimates & Trend Analysis
Chapter 8. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
- Ethicon
- Baxter International
- Corza Medical
- Integra LifeSciences Corporation
- Artivion
- Becton, Dickinson and Company (BD)
- Teleflex
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 125 |
| Published | May 2026 |
| Forecast Period | 2025 - 2033 |
| Estimated Market Value ( USD | $ 95.5 Million |
| Forecasted Market Value ( USD | $ 114.6 Million |
| Compound Annual Growth Rate | 2.3% |
| Regions Covered | United States |
| No. of Companies Mentioned | 7 |
